Matthew Taylor, DO
Pulmonary Disease · Sioux Falls, SDNPI 1699126946
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (52.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 83.9% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $5,223 and has fallen 74.6% since, to $1,326 in 2025.
Across 33 payments — averaging $231.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Boehringer Ingelheim$372
- United Therapeutics Corporation$255
- GSK$236
- Insmed, Inc.$159
- Gilead$121
- plus $84 from 3 others
What the payments were for
- Travel & lodging$1,82824%
- Food & beverage$1,78123%
- Education$4,03453%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 16 | $6,415 |
| Boehringer Ingelheim | 3 | $372 |
| United Therapeutics Corporation | 3 | $255 |
| GSK | 3 | $236 |
| Insmed, Inc. | 3 | $159 |
| Gilead | 1 | $121 |
| La Jolla Pharmaceutical Company | 2 | $35 |
| Baxter Healthcare | 1 | $29 |
| Inspire Medical Systems, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,157
- OFEV$372
- NUCALA$221
- Cayston$121
How this compares
$7,643 in reported general payments places this provider in the 85th percentile of 35 pulmonary disease providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 47 | $219,813 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 181 | $120,389 |
| Dupixent PenDupilumab | 26 | $92,372 |
| Breo ElliptaFluticasone/Vilanterol | 94 | $36,161 |
| Spiriva RespimatTiotropium Bromide | 66 | $34,692 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 55 | $31,962 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 41 | $29,217 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $21,134 |
| Advair HfaFluticasone Propion/Salmeterol | 46 | $20,486 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 24 | $9,856 |
| Incruse ElliptaUmeclidinium Bromide | 26 | $9,646 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 59 | $7,918 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $7,820 |
| EliquisApixaban | 13 | $7,599 |
| Varenicline Tartrate | 36 | $7,084 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $236 | $417,970403 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $372 | $63,909107 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 35 pulmonary disease providers in South Dakota.
Other pulmonary disease in Sioux Falls
- Joevasanth DevasahayamSioux Falls$8K
- Fady JamousSioux Falls$6K
- Rizan HajalSioux Falls$5K
- Kaitlin BranickSioux Falls$5K
- Anna PlemmonsSioux Falls$3K
- Mohammed AwadSioux Falls$2K
- Ashraf ElshamiSioux Falls$2K
- John YuSioux Falls$2K
- Rajaganesh RajagopalanSioux Falls$964
- Ross BaconSioux Falls$599
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.